Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial

• Published in: Respirology (Carlton, Vic.) Vol. 27; no. 9; pp. 758 - 766
• Main Authors: Mirahmadizadeh, Alireza, Semati, Ali, Heiran, Alireza, Ebrahimi, Mostafa, Hemmati, Abdolrasool, Karimi, Mohammadreza, Basir, Souzan, Zare, Marjan, Charlys da Costa, Antonio, Zeinali, Mohammad, Sargolzaee, Maryam, Eilami, Owrang
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01.09.2022; Wiley Subscription Services, Inc
• Subjects: Clinical trials; Coronaviruses; COVID-19; Dermatitis; Double-blind studies; efficacy; Hospitalization; Ivermectin; mild COVID‐19; Original; Patients; Placebos; randomized clinical trial; Respiratory diseases; Reverse transcription; SARS‐CoV‐2; Statistical analysis; Tachycardia

Background and objective Ivermectin is a known anti‐parasitic agent that has been investigated as an antiviral agent against coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin in mild COVID‐19 patients. Methods In this multi‐arm randomized clinical trial con...